Ledger.Open graph →
SEC Form D · filed February 25, 2026

Nasus Pharma Ltd

Offering
$15.0M
Sold
$15.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
TEL AVIV, L3
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (8)

David Silberman · New York, NYDirectorUdi Gilboa · TEL AVIV, L3DirectorDalia Megiddo · Fremont, CAExec · DirectorSharon Shacham · Cambridge, MADirectorEyal Rubin · NEW YORK, NYExecDan Teleman · Ness Ziona, L3Exec · DirectorRonnie Hershman · Lake Success, NYDirectorIsaac Israel · TEL AVIV, L3Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗